| Bioactivity | KU004 is a potent dual EGFR/HER2 inhibitor with anticancer effects. KU004 inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR and downstream Akt and Erk pathways and induces cell Apoptosis mainly via the extrinsic pathway. KU004 is a novel quinazoline derivative[1][2]. |
| CAS | 1260401-93-1 |
| Formula | C29H27ClFN4O2P |
| Molar Mass | 548.98 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tian C, et al. A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells. Apoptosis. 2015 Dec;20(12):1599-612. [2]. Tian C, et al. Inhibition of glycolysis by a novel EGFR/HER2 inhibitor KU004 suppresses the growth of HER2+ cancer. Exp Cell Res. 2017 Aug 15;357(2):211-221. |
KU004
CAS: 1260401-93-1 F: C29H27ClFN4O2P W: 548.98
KU004 is a potent dual EGFR/HER2 inhibitor with anticancer effects. KU004 inhibits the proliferation of human breast can
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.